Nicolas M Gonzalez-Senac

Dr. Nicolas M Gonzalez-Senac

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
NGNicolas M Gonzalez-Senac
Nicolas M Gonzalez-Senac
JMJennifer Mayordomo-Cava
Jennifer Mayordomo-Cava
AMAngela Macías-Valle
Angela Macías-Valle
PAPaula Aldama-Marín
Paula Aldama-Marín
SGSara Majuelos González
Sara Majuelos González
JSJosé Antonio Serra-Rexach
José Antonio Serra-Rexach
Six out of every 10 new colorectal cancer (CRC) diagnoses are in people over 65 years of age. Current standardized surgical approaches have proved to be tolerable on the elderly population, although post-operative complications are more frequent than in the younger CRC population. Frailty is common in elderly CRC patients with surgical indication, and it appears to be also associated with an increase of post-operative complications. Fast-track pathways have been developed to assure and adequate post-operative recovery, but comprehensive geriatric assessments (CGA) are still rare among the preoperative evaluation of elderly CRC patients. This review provides a thorough study of the effects that a CGA assessment and a geriatric intervention have in the prognosis of CRC elderly patients with surgical indication.

28 August 2024 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
CEColm Mac Eochagain
Colm Mac Eochagain
RPRobert Power
Robert Power
CSChristine Sam
Christine Sam
NGNicolas M Gonzalez-Senac
Nicolas M Gonzalez-Senac
DWDarren J. Walsh
Darren J. Walsh
Nicolò Matteo Luca BattistiNicolò Matteo Luca Battisti
Nicolò Matteo Luca Battisti
Immune checkpoint inhibitors (ICI) have transformed the management of cancer, particularly for older adults, who constitute a majority of the global cancer patient population. This study aimed to assess the inclusion, characteristics, and reporting of older adults enrolled in Food and Drug Administration (FDA) registration clinical trials of ICI between 2018 and 2022. Clinical trials of ICI leading to an FDA approval in solid tumor oncology between 2018 and 2022 were included. Primary study reports and all available secondary publications were assessed. The availability and completeness of older subgroup data for protocol-defined clinical efficacy endpoints, health-related quality of life (HRQOL) and toxicity outcomes, and baseline characteristics were assessed according to predefined criteria which categorized reporting completeness hierarchically in relation to the availability of published data, including effect size, sample size, and measures of precision. 53 registration trials were included, involving a total of 37,094 participants. Most trials (64.2%) were of ICI combination therapy. 42.3% of patients were aged≥65 years; 11.1% were aged≥75. No trials specified an upper age limit for eligibility. 98.1% of trials excluded patients with European Cooperative Oncology Group performance status>1. 87.2% of primary efficacy endpoints and 17.9% of secondary efficacy endpoints were reported completely for older adults. Five studies (9.4%) reported baseline characteristics, three (6.1%) reported HRQOL assessments, and four (7.5%) reported toxicity outcomes completely among older subgroups. No trials conducted baseline geriatric assessments or reported geriatric-specific symptoms or quality of life scales. This analysis highlights significant deficits in the enrollment and reporting of older subgroups in pivotal trials of ICI therapy. The findings highlight an urgent need for improved reporting and inclusion standards in clinical trials of ICI to better inform treatment decisions for older adults.

27 October 2022 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
NGNicolas M Gonzalez-Senac
Nicolas M Gonzalez-Senac
GSGema Somoza‐Fernandez
Gema Somoza‐Fernandez
EREsther Ocaña Ramirez
Esther Ocaña Ramirez
VRVicente Romero‐Estarlich
Vicente Romero‐Estarlich
FOFrancisco J. Ortiz‐Alonso
Francisco J. Ortiz‐Alonso
MVMaria T. Vidan
Maria T. Vidan

7 March 2023 in Revista Española de Geriatría y Gerontología
Verified
Journal Article
Closed access
NGNicolas M Gonzalez-Senac
Nicolas M Gonzalez-Senac
MRMyriam Rodríguez-Couso
Myriam Rodríguez-Couso

11 July 2026 in European Geriatric Medicine
Verified
Journal Article
Closed access
PDF file
MMMagdalena Linge Martín
Magdalena Linge Martín
GFGema Somoza Fernández
Gema Somoza Fernández
NGNicolas M Gonzalez-Senac
Nicolas M Gonzalez-Senac
ASAmaya Capón Sáez
Amaya Capón Sáez
JMJesús Mateos-Nozal
Jesús Mateos-Nozal
JSJosé Antonio Serra-Rexach
José Antonio Serra-Rexach

3 November 2018 in Revista Española de Geriatría y Gerontología
Verified
Journal Article
Closed access
NGNicolas M Gonzalez-Senac
Nicolas M Gonzalez-Senac
GFGema Somoza Fernández
Gema Somoza Fernández
MAMaría Ángeles García Alhambra
María Ángeles García Alhambra